In the latest sign of anger over the cost of insulin, the Minnesota attorney general on Tuesday filed a lawsuit accusing the three largest manufacturers — Eli Lilly, Sanofi and Novo Nordisk — with deceptively raising prices, the first state to go to court over the issue.

“Insulin is a life-or-death drug for people with diabetes,” said Minnesota Attorney General Lori Swanson in a statement. “Many people can’t afford the price hikes but can’t afford to stop taking the medication either.” As an example, the lawsuit cited the Lantus insulin sold by Sanofi, which cost $99.35 for a 10-milliliter vial in 2010, now costs $269.54.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • When I was on Medicare and a supplement insurance, I was paying $1000 a month for my insulin. Now, working for HealthPartners, I have excellent insurance and only pay $10 for a month’s worth of insulin. At $1000, I told my endocrinologist that it was either the mortgage or the insulin….I could not afford both.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy